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Purpose of Review: The intestinal allograft, with an enormous lymphoid load, is a highly 
immunogenic organ which elicits a strong alloimmune response. In the early post transplant 
period, a robust graft biopsy protocol via a temporary ileostomy is utilized for surveillance to 
detect rejection. In the later post-transplant period, after enteral continuity is re-established, 
graft biopsies via a colonoscopy become more cumbersome. Alternative methods for 
intestinal allograft monitoring other than graft biopsy are of particular interest. 
Recent Findings: Biomarkers and diagnostic tools such as Granzyme B, Perforin, fecal 
Calprotectin, Citrulline, donor specific antibody (DSA), and zoom video-endoscopy have all 
been studied for application as reliable methods of performing intestinal allograft 
surveillance.  Each modality has the capability of monitoring a separate and unique process in 
the host-allograft immune response.   
Summary: The goal to find a reliable , reproducible and non-invasive method for intestinal 
graft monitoring remains an elusive one. Many of the current modalities available only serve 
to act as complementary tests in conjunction with astute clinical observations. Graft biopsy 
remains the gold standard for monitoring the intestinal allograft.  
KEY POINTS:   
 Long-term outcome after intestinal transplantation is still negatively affected by 
rejection 
 Better graft monitoring , other than biopsy, could reduce late allograft loss 
 Video-endoscopy is a reliable diagnostic tool but in expert hands 
 Molecules such as Granzyme B and Perforin, Citrulline or Calprotectin so far have 
shown questionable results in allograft surveillance 







Intestinal transplantation (ITx) has shown steady improvements in graft and patient survival 
over the past 20 years, particularly with short-term results. Lasting improvements in long-
term outcome, however, still remain a challenge. Late allograft loss due to acute rejection (AR) 
still remains a vexing problem, in particular due to the challenge of diagnosing AR in a stable 
recipient long removed from an aggressive, biopsy-driven, early post-transplant monitoring 
protocol.  Biopsy is the gold standard for the diagnosis of ITx allograft pathology. Currently we 
lack a reliable biomarker able to forewarn of rejection episodes: we herein review recently 
published data of non-invasive allograft monitoring after ITx.  
 
MONITORING OF THE IMMUNE SYSTEM: 
In kidney or liver transplant, blood tests such as creatinine level or liver function tests are 
suitable to determine if there is graft dysfunction: such a simple and reproducible biomarker 
has yet to be discovered in ITx. Currently, ITx monitoring is based on protocol biopsies. 
However, this is an invasive procedure which requires a skilled operator as well as an 
experienced histopathologist. An ideal biomarker should be non-invasive, reproducible, and 
with a rapid result allowing for the initiation of prompt treatment. 
 
- Granzyme B and Perforin : 
Similarly to kidney transplantation, the Bologna group (1-4) analyzed the blood expression of 
Granzyme B (GB) and Perforin (PF) after ITx  by real time polymerase chain reaction (PCR) on 
32 recipients (494 blood samples) during episodes of AR, Epstein-Barr virus (EBV) or 
cytomegalovirus (CMV) infection, and post-transplant lymphoproliferative disease (PTLD).  
Both GB and PF are expressed in natural killer cells and cytotoxic T lymphocytes, acting as 
effector molecules for the induction of apoptosis in target cells. The inability to use the test in 
the first 28 days because of variable expression was a limiting factor. Mean levels of GB and 
PF in the AR (GB=279.7; PF=256.7), PTLD (GB=199; PF=185.9), EBV (GB=133.2; PF=143.7), 
and CMV (GB=151.3; PF=144) groups were significantly higher than in the normal group 
(GB=100.1; PF=101.1) (all P<0.05, except for PF in CMV infection). Although the best accuracy 
was obtained for the diagnosis of AR, half of the samples were eliminated due to confounding 
conditions, limiting the clinical applicability. Sensitivity and specificity were 80% and 79% for 
GB and 70% and 79% for PF, respectively, and the area under the receiver-operator 
characteristics (ROC) curve was 0.87 for GB and 0.82 for PF. GB and PF levels rose in only 10 
of 30 episodes of rejection from eight patients at a mean of 14 days (range 3–38) prior to AR. 
Their conclusion was that GB and PF are diagnostic markers of AR even though the levels also 
increase in case of viral infections or PTLD. GB and PF might act as predictive molecules but 
should be interpreted in a clinical, histological and virological context. Therefore, their utility 
is questionable.  
 
- Fecal Calprotectin: 
Fecal Calprotectin have been widely correlated with inflammatory bowel disease activity, 
proposing it as potential marker of ITx rejection. In an early Omaha study, fecal Calprotectin 
levels were measured from ileostomy of 68 recipients with AR (n =12), viral enteritis (n= 5), 
and nonspecific inflammation (n =16), and compared with 35 normal controls (5). During AR 
episodes, fecal Calprotectin was significantly higher than in viral enteritis or normal controls  
(198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)), and the cut-off level 
was 92 mg/kg with specificity of 77% and sensitivity of 83%, as suggested by receiver 
operator characteristics (ROC). In a follow-up study by the same group, published in 2011 (6-
7), 732 stool samples were collected from 72 recipients: due to significant inter-patient 
variability, defining an effective general “cutoff” level was difficult and not clinically 
applicable. A Miami study (8) measured fecal Calprotectin on 29 recipients and a cut-off level 
of 100 ng/mg was considered positive. Retrospective evaluation of 122 samples revealed non-
specific results. The assay was sensitive to the identification of intestinal illnesses in general, 
but not useful in specifically distinguishing AR from these ongoing organic intestinal 
problems. Finally a report from Argentina (9) showed a good sensitivity but low specificity 
for the diagnosis of intestinal AR. High Calprotectin levels were also observed in other clinical 
conditions. In summary, a clear role for Calprotectin as a marker of rejection has yet to be 
realized. 
 - Citrulline: 
Serum Citrulline is a non-protein amino acid deriving from glutamine conversion within 
enterocytes, studied as a marker of functional enterocyte mass in short bowel syndrome. The 
Miami group (10-14) analyzed 2135 dried blood spots from 57 intestinal transplant 
recipients at or beyond 3 months post-transplant. Lower Citrulline levels were found in 
presence of mild, moderate, or severe AR, bacteremia or respiratory infection, in the pediatric 
age group, and were dependent upon the time from transplant. Using a <13 vs. =/>13 
µmoles/L as a cutoff point, levels =/>13 µmoles/L were associated with moderate or severe 
rejection. They confirmed their data in 2012 (15), concluding that Citrulline in ITx may serve 
as a non invasive biomarker with excellent negative predictive values in the long term follow-
up of pediatric recipients. On the contrary, a New York study (16-18) reported that Citrulline 
reflects the extent of mucosal injury regardless of the etiology, but does not seem to be a 
predictive marker for rejection or viral enteritis, as its values may decline only when diffuse 
mucosal damage has occurred. These last results were confirmed by a Madrid group (19): 
they reported Citrulline as a sensitive and specific biomarker of the residual functional 
enterocyte load, related to enteric feeding tolerance, but its prognostic value as a rejection 
marker was questionable. Recently, a Bologna study (20) investigated Citrulline according to 
time from ITx, episodes of AR and creatinine clearance. Twenty-four adult recipients were 
prospectively studied. The results were compared with those of 19 healthy controls and of 29 
patients with chronic renal failure. Citrulline sensitivity and specificity in detecting AR after 
the 45th post-operative day were 38% and 83% using Citrulline threshold observed in healthy 
controls, and 69% and 77% using Citrulline threshold adjusted for chronic renal failure 
degree. Their conclusion was that adjusting Citrulline threshold for chronic renal failure 
degree almost doubled the sensitivity of Citrulline as a non-invasive marker of AR in ITx. 
Summarizing the reported studies, Citrulline probably expresses an exclusionary role because 
its higher levels are unlikely correlated with severe AR, and its major limitation is a lack of 
forewarning of AR episodes.  
 
- Donor Specific Antibodies: 
Donor specific antibodies (DSAs) represent the humoral alloimmunity against donor antigens: 
it has been widely established in other solid organ transplants that DSAs contribute to 
rejection and late allograft loss. After ITx, pre-transplant (pre-formed) DSAs are present in 
nearly one-third of patients and post-transplant (de novo) DSAs develop in up to 40% of 
recipients. Recent literature shows that pre-formed and/or de novo DSAs are correlated with 
ITx rejection and allograft loss. A Pittsburgh report in 2000 (21) addressed the impact of 
DSAs, reporting that a positive T-cell lymphocytotoxic cross-match increases the frequency 
and severity of rejection after ITx, particularly with isolated bowel graft. In 2010, the Los 
Angeles group (22) showed that DSAs were associated with higher allograft loss and 
mortality while a Miami study (23) correlated DSAs with more frequent and severe episodes 
of rejection (P=0.041). In the Miami report DSAs were pre-formed (n=5, anti-human leukocyte 
antigen class II=3, anti-class I and II=2), de novo (n=4, 15.25±4.72 days after transplantation, 
anti-class II=1, and anti-class I and II=3) and never (n=6). Among 63 biopsies, 30 (47.6%) had 
significant correlations with positive DSA (kappa=0.30, P<0.001) and manifested severe 
rejection grade (P=0.009). In 2012, a Pittsburgh study (24) analyzed 194 primary adult 
recipients: complement-dependent lymphocytotoxic cross-match (CDC-XM) was positive in 
55 (28%). HLA-DSA was detectable before transplant in 49 (31%) recipients with 19 
continuing to have circulating antibodies. Another 19 (18%) developed de novo DSAs. Ninety 
percent of patients with pre-formed DSAs harbored HLA Class-I, whereas 74% of recipients 
with de novo antibodies had Class-II. Most antibody-mediated rejection (AMR) cases occurred 
in the first 3 months after transplant and patients with persistent DSAs exhibited the highest 
risk of AMR. Pre-formed DSAs significantly (p < 0.05) increased the risk of AR. Persistent and 
de novo HLA-DSA significantly (p < 0.001) increased risk of chronic rejection and associated 
graft loss. Inclusion of the liver was a significant predictor of better outcome (p = 0.004, HR = 
0.347) with significant clearance of pre-formed antibodies (p = 0.04, OR = 56) and lower 
induction of de novo DSAs (p = 0.07, OR = 24). The Berlin group (25) recently confirmed that 
the development of de novo DSAs following ITx is often associated with AR, observing that the 
number of mismatched antigens and epitopes correlates with the probability of developing de 
novo DSAs. Different results were shown in a 2013 study by the Indianapolis group (26): of 
131 intestinal/multivisceral transplants, 27 (21%) had a positive flow cytometry cross-match 
(FCXM). Positive cross-match was not associated with an increased incidence of AR and graft 
loss (30% and 37% vs. 29% and 47%; P=0.94 and 0.35, respectively). This effect was 
maintained in liver-excluding transplants. The authors attributed their positive outcome to 
the immunosuppressive regimen based on induction by thymoglobulin and rituximab, and 
maintenance with tacrolimus and prednisone plus monthly doses of anti-interleukin-2 
receptor antibody (IL-2RA) for the recipients of liver-free allografts. However, cross-matching 
patients was based on the less sensitive FCXM assay compared to a Luminex-based assay, thus 
may be underestimating the impact of DSAs (23). The virtual cross-match (VXM), in which 
known recipient HLA antibodies are prospectively compared to donor HLA type, provides one 
mean to optimize organ allocation and minimize immunologic risk. In fact, the VXM was 
recently shown (27) by the Washington DC group to allow for successful isolated ITx with 
acceptable short-term outcomes in sensitized patients. A number of papers have been 
presented at the recent Intestinal Small Bowel Transplant Symposium (ISBTS) held in June 
2015 in Argentina. A Los Angeles report (28) confirmed that the presence of pre-formed or de 
novo DSAs leads to inferior survival outcomes following ITx. A study from the Washington DC 
group (29) showed that the development of de novo DSAs occurs at a rapid and high 
incidence after ITx. Their monitoring included weekly DSA analysis for 2 months, then 
monthly testing for the remaining year. If de novo DSAs appeared, then weekly monitoring 
was reinstituted. De novo DSAs developed in 32% recipients at a median time of 22.5 days 
after transplant. Liver inclusion was not associated with any difference in the development of 
de novo DSAs (p =0. 21) as confirmed by another paper from the Palo Alto group (30). The 
Indiana team also performed DSA monitoring and noted that the development of de novo DSA 
had a trend towards the development of chronic rejection (14% vs 5%, p = 0.21) and graft 
loss due to AR (18% vs 7%, p= 0.14) (31). Boluda et al. from Madrid (32) showed that the 
presence of DSAs is linked to re-transplantation, being unusual in candidates for first 
transplant. In summary, there is still some debate going on regarding the impact of DSAs and 
its use as an ITx graft monitoring tool, but a large amount of evidence shows that the presence 
of de novo or pre-formed DSAs is involved negatively in long-term graft survival. New 
therapeutic strategies have been developed in recent years (33-36) to treat DSAs, but their 
description is beyond the scope of the present review. 
 
VISUAL MONITORING OF THE GRAFT: 
Visual graft surveillance is the easiest one over other forms of monitoring after solid organ 
transplantation, due to the graft ileostomy manufactured for biopsy. Ideally, endoscopy itself 
through the ileostomy (or, when the stoma has been taken down, a gastroscopy or 
colonoscopy) should be able to monitor the graft, avoiding the more invasive biopsy 
procedure with the possible hazards of mucosal hematomas, bleeding and perforations, 
especially in small and/or friable grafts. The Pittsburgh group examined (37) this issue, 
documenting that endoscopy alone would have missed 37% of cases of AR in 1273 
endoscopies performed in 41 children. In their initial study they used fiber-optic endoscopy, 
but 8 years later (38), with the improved magnification and optical resolution, new video 







- Zoom Videoendoscopy: 
In 2006, the Miami group (38) analyzed the video-endoscopic diagnosis of rejection, 
comparing it to histological findings. Adult patients showed a sensitivity of 45%, a specificity 
of 98%, a positive predictive value of 82%, and a negative predictive value of 88%. The most 
intriguing aspect of this study was that, on 59 distinct occasions in which the results were 
endoscopy-negative but biopsy-positive for AR, rejections were not treated on the basis of 
clinical evaluation and 58 (98%) resolved without further therapy. More recently a Bologna 
study (39-40) evaluated 52 protocol endoscopies over a period of 2 years on 17 adult 
recipients with more than 5 years follow-up. All the 52 endoscopic findings were comparable 
to biopsy-definitive results (specificity was 98%): only 1 case of mild enteritis and 1 case of 
EBV chronic infection at biopsy were not diagnosed by endoscopy, while no episodes of 
rejection were diagnosed either by biopsy or endoscopy because the study group was 
represented by stable recipients in long-term follow-up.  Conversely, the Pittsburgh group in 
2012 (41) reported different results, analyzing a number of adult endoscopies performed in 
66 asymptomatic ‘‘surveillance’’ recipients and 71 symptomatic recipients. For surveillance 
patients, 125 ileoscopies were performed to collect 590 biopsies, and for the symptomatic 
group 229 ileoscopies and jejunoscopies were conducted to obtain 434 biopsies. The 
sensitivity and specificity of endoscopic visualization in detecting AR was 50% and 91.5% for 
the surveillance group and 43% and 67% for the symptomatic patients respectively. In 
surveillance, visual impression alone would have missed three cases of moderate and no cases 
of severe AR, while in the symptomatic group visual inspection alone would have missed 20 
cases of moderate AR. Their conclusion was that in symptomatic patients, visual inspection 
detected all cases of severe rejection but would have missed patients with early readily 
treatable rejection, supporting the current clinical practice of ileoscopic biopsy for graft 
surveillance in asymptomatic patients.  
 CONCLUSION: 
In conclusion, over the last 15 years there have been many attempts to find an alternative to 
biopsy for prevention and/or diagnosis of AR, in order to improve long-term graft survival 
after intestinal transplantation (Table 1). Serum or fecal biomarkers (Granzyme B and 
Perforin, Citrulline, Calprotectin) have been analyzed by many groups and, although 
promising to monitor the immune system, so far they have missed their role substituting the 
gold standard biopsy. Recently, DSAs have shown a link to graft survival, but their clinical 
significance in a day-by-day laboratory monitoring is still far from being fully understood. 
Zoom video-endoscopy has been identified as a useful tool to support biopsy findings, but its 
exclusionary role as non-invasive marker of the intestinal graft probably requires technology 
innovations still not available on the scientific market. 
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